Albumin nanoparticles and their folate modified counterparts for delivery of a lupine derivative to hepatocellular carcinoma
In this study, folate polyethylene glycol CTr albumin nanoparticles (FA-PEG-CTr-NPs) targeting hepatocellular carcinoma (HCC) were prepared. The nanoparticle preparation method was optimized using single-factor and response surface analysis. The prepared nanoparticles were characterized for their pa...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-11-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223012830 |
| _version_ | 1797660613905743872 |
|---|---|
| author | Haohao Wang Di Wu Pan Wang Chunyu Gao Hongbo Teng Dong Liu Yan Zhao Rui Du |
| author_facet | Haohao Wang Di Wu Pan Wang Chunyu Gao Hongbo Teng Dong Liu Yan Zhao Rui Du |
| author_sort | Haohao Wang |
| collection | DOAJ |
| description | In this study, folate polyethylene glycol CTr albumin nanoparticles (FA-PEG-CTr-NPs) targeting hepatocellular carcinoma (HCC) were prepared. The nanoparticle preparation method was optimized using single-factor and response surface analysis. The prepared nanoparticles were characterized for their particle size, zeta potential, and morphology. The particle size and zeta potential were also determined. Additionally, drug loading, encapsulation efficiency, and in vitro drug release of the nanoparticles were determined. Using the Cell Counting Kit-8 method, their cytotoxicity and their cell-targeted uptake were determined using confocal microscopy and flow cytometry. Finally, the in vivo antitumor impact and tumor-targeting ability of the nanoparticles were evaluated by determining tumor volume inhibition and drug biodistribution and performing hematoxylin-eosin (H&E) staining. It was found that CTr could be effectively encapsulated into albumin nanoparticles and functionalized. The drug loading of the two nanoparticles was 67.12 ± 2.4% and 69.33 ± 2.8%, respectively. Regarding drug release, FA-PEG-CTr-NPs (89.0%) exhibited a superior release rate to CTr-NPs (70.5%) in an acidic environment. The in vitro experiments confirmed that FA-PEG-CTr-NPs yielded better cytotoxicity and faster drug uptake results than CTr and CTr-NPs. In vivo experiments confirmed that FA-PEG-CTr-NPs exhibited markedly better tumor inhibitory activity (inhibition rate was 80.21%), drug safety, and targeting than CTr and CTr-NPs. In conclusion, functionalized nanoparticles (FA-PEG-CTr-NPs) can specifically inhibit the malignant proliferation of HCC cells and are thus a promising nanoagent for the treatment of HCC. |
| first_indexed | 2024-03-11T18:32:26Z |
| format | Article |
| id | doaj.art-ef05716104e74a098e74a6b425cb31e5 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-11T18:32:26Z |
| publishDate | 2023-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-ef05716104e74a098e74a6b425cb31e52023-10-13T11:02:47ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-11-01167115485Albumin nanoparticles and their folate modified counterparts for delivery of a lupine derivative to hepatocellular carcinomaHaohao Wang0Di Wu1Pan Wang2Chunyu Gao3Hongbo Teng4Dong Liu5Yan Zhao6Rui Du7School of biological and pharmaceutical engineering, West Anhui University, Lu’an 237012, ChinaDepartment of Breast Surgery, General Surgery Center, First Hospital of Jilin University, Changchun 130118, ChinaSchool of biological and pharmaceutical engineering, West Anhui University, Lu’an 237012, ChinaCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, ChinaCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, ChinaSchool of biological and pharmaceutical engineering, West Anhui University, Lu’an 237012, China; Anhui Traditional Chinese Medicine Ecological Agricultural engineering Research Center, Lu’an 237012, China; Correspondence to: School of biological and pharmaceutical engineering, West Anhui University, Lu’an 237012, Anhui, China.College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China; Correspondence to: College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, Jilin, China.College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, ChinaIn this study, folate polyethylene glycol CTr albumin nanoparticles (FA-PEG-CTr-NPs) targeting hepatocellular carcinoma (HCC) were prepared. The nanoparticle preparation method was optimized using single-factor and response surface analysis. The prepared nanoparticles were characterized for their particle size, zeta potential, and morphology. The particle size and zeta potential were also determined. Additionally, drug loading, encapsulation efficiency, and in vitro drug release of the nanoparticles were determined. Using the Cell Counting Kit-8 method, their cytotoxicity and their cell-targeted uptake were determined using confocal microscopy and flow cytometry. Finally, the in vivo antitumor impact and tumor-targeting ability of the nanoparticles were evaluated by determining tumor volume inhibition and drug biodistribution and performing hematoxylin-eosin (H&E) staining. It was found that CTr could be effectively encapsulated into albumin nanoparticles and functionalized. The drug loading of the two nanoparticles was 67.12 ± 2.4% and 69.33 ± 2.8%, respectively. Regarding drug release, FA-PEG-CTr-NPs (89.0%) exhibited a superior release rate to CTr-NPs (70.5%) in an acidic environment. The in vitro experiments confirmed that FA-PEG-CTr-NPs yielded better cytotoxicity and faster drug uptake results than CTr and CTr-NPs. In vivo experiments confirmed that FA-PEG-CTr-NPs exhibited markedly better tumor inhibitory activity (inhibition rate was 80.21%), drug safety, and targeting than CTr and CTr-NPs. In conclusion, functionalized nanoparticles (FA-PEG-CTr-NPs) can specifically inhibit the malignant proliferation of HCC cells and are thus a promising nanoagent for the treatment of HCC.http://www.sciencedirect.com/science/article/pii/S0753332223012830Hepatocellular carcinomaNanoparticlesFolateTargetH22 |
| spellingShingle | Haohao Wang Di Wu Pan Wang Chunyu Gao Hongbo Teng Dong Liu Yan Zhao Rui Du Albumin nanoparticles and their folate modified counterparts for delivery of a lupine derivative to hepatocellular carcinoma Biomedicine & Pharmacotherapy Hepatocellular carcinoma Nanoparticles Folate Target H22 |
| title | Albumin nanoparticles and their folate modified counterparts for delivery of a lupine derivative to hepatocellular carcinoma |
| title_full | Albumin nanoparticles and their folate modified counterparts for delivery of a lupine derivative to hepatocellular carcinoma |
| title_fullStr | Albumin nanoparticles and their folate modified counterparts for delivery of a lupine derivative to hepatocellular carcinoma |
| title_full_unstemmed | Albumin nanoparticles and their folate modified counterparts for delivery of a lupine derivative to hepatocellular carcinoma |
| title_short | Albumin nanoparticles and their folate modified counterparts for delivery of a lupine derivative to hepatocellular carcinoma |
| title_sort | albumin nanoparticles and their folate modified counterparts for delivery of a lupine derivative to hepatocellular carcinoma |
| topic | Hepatocellular carcinoma Nanoparticles Folate Target H22 |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223012830 |
| work_keys_str_mv | AT haohaowang albuminnanoparticlesandtheirfolatemodifiedcounterpartsfordeliveryofalupinederivativetohepatocellularcarcinoma AT diwu albuminnanoparticlesandtheirfolatemodifiedcounterpartsfordeliveryofalupinederivativetohepatocellularcarcinoma AT panwang albuminnanoparticlesandtheirfolatemodifiedcounterpartsfordeliveryofalupinederivativetohepatocellularcarcinoma AT chunyugao albuminnanoparticlesandtheirfolatemodifiedcounterpartsfordeliveryofalupinederivativetohepatocellularcarcinoma AT hongboteng albuminnanoparticlesandtheirfolatemodifiedcounterpartsfordeliveryofalupinederivativetohepatocellularcarcinoma AT dongliu albuminnanoparticlesandtheirfolatemodifiedcounterpartsfordeliveryofalupinederivativetohepatocellularcarcinoma AT yanzhao albuminnanoparticlesandtheirfolatemodifiedcounterpartsfordeliveryofalupinederivativetohepatocellularcarcinoma AT ruidu albuminnanoparticlesandtheirfolatemodifiedcounterpartsfordeliveryofalupinederivativetohepatocellularcarcinoma |